Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated nonsmall-cell lung cancer: A meta-analysis of 13 randomized trials

Clinical Lung Cancer

Volumn 13, Issue 2, 2012, Pages 107-114

  Petrelli, Fausto ^a   Borgonovo, Karen ^a   Cabiddu, Mary ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

EGFR; Erlotinib; Gefitinib; Mutation; Nonsmall cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL;

CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; DRUG EFFICACY; GENE MUTATION; HAZARD RATIO; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; RISK FACTOR; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84857414572     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.08.005     Document Type: Review

References (47)

1. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
2. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
3. W. Pao, V. Miller, M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311 (Pubitemid 39209661)
4. I.J. Dahabreh, H. Linardou, F. Siannis Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer Clin Cancer Res 16 2010 291 303
5. S.W. Han, T.Y. Kim, P.G. Hwang Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2005 2493 2501
6. F. Cappuzzo, F.R. Hirsch, E. Rossi Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 2005 643 655 (Pubitemid 40812628)
7. T.Y. Chou, C.H. Chiu, L.H. Li Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer Clin Cancer Res 11 2005 3750 3757
8. H. Cortes-Funes, C. Gomez, R. Rosell Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients Ann Oncol 16 2005 1081 1086 (Pubitemid 41418309)
9. X.T. Zhang, L.Y. Li, X.L. Mu The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced nonsmall-cell lung cancer Ann Oncol 16 2005 1334 1342
10. T. Takano, Y. Ohe, H. Sakamoto Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2005 6829 6837
11. A. Inoue, T. Suzuki, T. Fukuhara Prospective phase II study of gefitinib for chemotherapy-nave patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations J Clin Oncol 24 2006 3340 3346 (Pubitemid 46638887)
12. H. Asahina, K. Yamazaki, I. Kinoshita A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations Br J Cancer 95 2006 998 1004 (Pubitemid 44606825)
13. A. Sutani, Y. Nagai, K. Udagawa Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp Br J Cancer 95 2006 1483 1489 (Pubitemid 44863350)
14. K. Yoshida, Y. Yatabe, J.Y. Park Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer J Thorac Oncol 2 2007 22 28 (Pubitemid 47163924)
15. N. Sunaga, Y. Tomizawa, N. Yanagitani Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy Lung Cancer 56 2007 383 389 (Pubitemid 46679091)
16. K. Tamura, I. Okamoto, T. Kashii Multicentre prospective phase II trial of gefitinib for advanced non small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) Br J Cancer 98 2008 907 914 (Pubitemid 351341609)
17. K. Sugio, H. Uramoto, T. Onitsuka Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations Lung Cancer 64 2009 314 318
18. S.V. Sharma, D.W. Bell, J. Settleman Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
19. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
20. European Medicines Agency http://www.ema.europa.eu/ema/index.jsp?curl=/ pages/home/Home-Page.jsp Accessed: September 22, 2011
21. M.K. Parmar, V. Torri, L. Stewart Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 17 1998 2815 2834 (Pubitemid 28562978)
22. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
23. J.Y. Douillard, F.A. Shepherd, V. Hirsh Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 28 2010 744 752
24. T. Mitsudomi, S. Morita, Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
25. F. Cappuzzo, T. Ciuleanu, L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
26. M.S. Tsao, A. Sakurada, J.C. Cutz Erlotinib in lung cancermolecular and clinical predictors of outcome N Engl J Med [published correction appears in N Engl J Med 2006; 355:1746] N Engl J Med 353 2005 133 144 (Pubitemid 41058345)
27. D.W. Bell, T.J. Lynch, S.M. Haserlat Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol 23 2005 8081 8092 (Pubitemid 46657411)
28. Yang CH, Fukuoka M, Mok TS, et al. Final overall survival (OS) results from a phase III, randomized, open-label, first-line study of gefitinib (G) v carboplatin/ paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). Program and abstracts of the 35th European Society for Medical Oncology Congress; October 8-12, 2010; Milan, Italy. Abstract LBA2.
29. Zhou C, Wu YL, Chen G, et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (gem), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pt) with EGFR activating mutations. Program and abstracts of the 35th European Society for Medical Oncology Congress; October 8-12, 2010; Milan, Italy (abstract LBA13).
30. B. Johnson, V. Miller, L. Amler Biomarker evaluation in the randomized, double-blind, placebo-controlled, phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advance EJC Supplements 7 2009 5
31. M. Kris, T. Mok, E. Kim Response and progression-free survival in 1006 patients with known EGFR mutation status in phase III randomized trials of gefitinib in individuals with non-small cell lung cancer EJC Supplements 7 2009 505 (abstract O-9003)
32. Lee JS, Park K, Kim S-W, et al. A randomized phase III study of gefitinib (IRESSA™) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. IASLC World Lung Conference on Lung Cancer. San Francisco, California, July 31-August 4, 2009 (abstract PRS.4).
33. D.A. Eberhard, B.E. Johnson, L.C. Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
34. R. Rosell, T. Moran, C. Queralt Spanish Lung Cancer Group Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
35. C. Gridelli, F. Ciardiello, R. Feld International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): the TORCH trial J Clin Oncol 28 suppl 2010 15 www.asco.org Accessed: September 22, 2011
36. V.A. Miller, P. O'Connor, C. Soh A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol 27 suppl 2010 18 abstract LBA8002 www.asco.org Accessed: September 22, 2011
37. Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 28(suppl): 15 (abstract 7507).
38. Gaafar RM, Surmont V, Scagliotti G, et al. A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). J Clin Oncol 28(suppl): 15 (abstract 7518).
39. D.M. Jackman, V.A. Miller, L.A. Cioffredi Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small-cell lung cancer patients: results of an online tumor registry of clinical trials Clin Cancer Res 15 2009 5267 5273
40. S. Kobayashi, T.J. Boggon, T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792 (Pubitemid 40271173)
41. W. Pao, V.A. Miller, K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
42. Y.Y. Janjigian, B.J. Park, M.F. Zakowski Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations J Thorac Oncol 6 2011 569 575
43. J.D. Goss, I. Lorimer, M.S. Tsao A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 J Clin Oncol 28 suppl 2010 18s (abstract LBA7005)
44. E. Bria, M. Milella, F. Cuppone Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis Ann Oncol 2011 Feb 16 [Epub ahead of print]
45. R. Rosell, R. Gervais, A. Vergnenegre Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial J Clin Oncol 29 suppl 2011 abstract 7503
46. R. Maruyama, Y. Nishiwaki, T. Tamura Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer J Clin Oncol 26 2008 4244 4252
47. N. Thatcher, A. Chang, P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537 (Pubitemid 41540110)